Role of Gas6 and TAM Receptors in the Identification of Cardiopulmonary Involvement in Systemic Sclerosis and Scleroderma Spectrum Disorders

Table 1

Characteristics and main comorbidities of the study population. The continuous variables are expressed as median (interquartile range), while the categorical variables as number (and frequency %).

Age, years	66 [56-75]
Gender, F/M	113/12
Disease duration, years	8 [3-13]
Smoking status, no/past smoker/active smoker	87(70)/20(16)/18(14)
Arterial hypertension	66 (57)
COPD	14 (11)
Cardiac disease	21 (17)
Liver disease/liver cirrhosis	18 (14)/0(0)
SS/MCTD/SS overlap	94(75)/13(10)/18(15)
Digital ulcer (past/active)	64(51)/13(10)
Anti-centromere/anti-Scl70/anti-U1RNP	67(54)/30(24)/28(22)
Arterial vasodilators: ERA/PDE5-I/iloprost	18(14)/7(6)/60(48)
PDN/HCQ/MTX	44(35)/66(53)/12(9)

Abbreviations: F: female; M: male; COPD: chronic obstructive pulmonary disease; SS: systemic sclerosis; MCTD: mixed connective tissue disease; SSD: scleroderma spectrum disorder; PAH: pulmonary arterial hypertension; ERA: endothelin receptor antagonist; PDE5-I: phosphodiesterase 5 inhibitor; PDN: prednisone; HCQ: hydroxychloroquine; MTX: methotrexate. Chronic heart failure and/or coronary artery disease.